Drugs / Monovalent Tetanus vaccine
Monovalent Tetanus vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00928785 Comparator | Jul → Dec 2009 | — | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Monovalent Tetanus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00928785 ↗ |
| Known as | Tetavax | “tetanus monovalent vaccine (TMV; Vaccin Tétanique Pasteur® or Tetavax®)” PMID 23032160 ↗ Oct 2012 |
| Known as | TMV | “tetanus monovalent vaccine (TMV; Vaccin Tétanique Pasteur® or Tetavax®)” PMID 23032160 ↗ Oct 2012 |
| Known as | Vaccin Tétanique Pasteur | “tetanus monovalent vaccine (TMV; Vaccin Tétanique Pasteur® or Tetavax®)” PMID 23032160 ↗ Oct 2012 |
| Modality | Vaccine | “tetanus monovalent vaccine (TMV; Vaccin Tétanique Pasteur® or Tetavax®)” PMID 23032160 ↗ Oct 2012 |